Praxis Precision Medicines (PRAX) said Thursday that the US Food and Drug Administration has set PDUFA target action dates of Dec. 26 for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies and Jan. 29, 2027, for ulixacaltamide in essential tremor.
The biopharmaceutical company said that the relutrigine field team is fully hired and has profiled all of its top 10 accounts per region, as well as tier 1 and tier 2 target health care professionals ahead of the target action date.
Additionally, the ulixacaltamide field team is expected to be fully hired before the end of the year to cover about 19,000 target health care professionals, Praxis said.
Comments